ImageneBio, Inc. (IMA)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralImageneBio ist trotz des KI-anmutenden Namens (eine Eindeutschung von »Inmagene«, dem fusionierten Biopharma-Unternehmen) eine klinische Ein-Produkt-Biotech: Leit- und einziger Wirkstoff ist der nicht-depletierende Anti-OX40-Antikörper IMG-007 gegen Neurodermitis. Kein KI-Produkt, kein KI-Umsatz (die Firma erzielt überhaupt keinen Produktumsatz), also kein »verkauft«. Kein »bedroht«: In den Risk Factors taucht »artificial intelligence« nur als generische Bedrohungs-/Regulierungs-Floskel auf (KI-gestützte Cyberangriffe, Deep Fakes, KI-Sektor-Regulierung nach OISP) ohne konkreten Bezug zum eigenen Geschäftsmodell. Auch kein »nutzt«: Der einzige Hinweis auf tatsächlichen KI-Einsatz ist ein beiläufiger Satz innerhalb eines Datenschutz-Risikofaktors, wonach Mitarbeiter generative KI-Werkzeuge bei ihrer Arbeit nutzen — kein dokumentiertes, wertschöpfendes KI-Programm (Effizienz/interne Produkte). Nach dem Kriterienkatalog verbleibt damit »Neutral« mit dokumentiertem Negativ-Befund; alle sechs ausgewerteten Filings sind gelistet.
View the full file — quotes, sources, reviewed filings
„As a result of the Non-OX40 Divestiture, IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of AD and other potential indications, became the only product candidate we have in clinical development."
Infolge der Non-OX40-Abspaltung wurde IMG-007, ein nicht-depletierender monoklonaler Anti-OX40-Antikörper zur Behandlung von Neurodermitis und weiteren möglichen Indikationen, zum einzigen Produktkandidaten, den wir in klinischer Entwicklung haben.
„Our personnel use generative artificial intelligence (“AI”) technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter nutzen generative Technologien der Künstlichen Intelligenz („KI“) bei ihrer Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und weiteren Datenschutzpflichten.
Filings Reviewed: 10-Q 2026-05-07 · 10-Q 2025-11-12 · 10-Q 2025-07-24 · 10-Q 2025-05-08 · 10-K 2026-03-10 · 10-K 2025-03-06
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.81 | – | 0 | -100.00 | – | -6 | -6 |
| 2025: Q1 | -0.76 | – | 1 | – | -1,077.40 | -11 | -11 |
| 2025: Q2 | -0.25 | – | – | – | – | -3 | -3 |
| 2025: Q3 | -2.20 | – | 0 | -100.00 | – | -27 | -27 |
| 2025: Q4 | -0.61 | – | 0 | – | – | -7 | -7 |
| 2026: Q1 | -0.94 | – | 0 | -100.00 | – | -15 | -15 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
ImageneBio, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt Therapeutika für Patienten mit immunologischen, autoimmunen und entzündlichen Erkrankungen.
| Employees | 17 |
|---|---|
| Headquarters | San Diego, CA |
| Website | inmagenebio.com |
| IPO Date | 26. Mar 2021 |
| Next Earnings | 23. Jul 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kristin Yarema Ph.D. | CEO, Director & Interim Principal Financial Officer | 1971 |
| Bob Lally | Senior VP of Finance & Operations and Principal Accounting Officer | 1963 |
| Kurinji Pandiyan Ph.D. | Chief Strategy & Operations Officer | – |
| Renuka Sivendran Ph.D. | Chief Technical Officer | – |
| Benjamin Porter-Brown M.D. | Chief Medical Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.